Monoclonal Antibody Kills Chronic Lymphocytic Leukemia Cells

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San Diego, Moores Cancer Center have discovered a humanized monoclonal antibody that targets and kills chronic lymphocytic leukemia.

The discovery could mean a new treatment pathway for patients with chronic lymphocytic leukemia (CLL) one of the most common hematologic cancers in the U.S.

Previous research has determined that CLL cells over-express the cell-surface glycoprotein receptor CD44. Thus San Diego researchers led by principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, along with their colleagues, uncovered a monoclonal antibody called RG7356, which specifically seeks CD44 on the cell surface.

RG7356 proved to be fatally toxic to the CLL cells while exhibiting little effect on other, healthy cells.

RG7356 also caused cell death in CLL cells that expressed levels of the ZAP-70 protein. This is good news since the disease in about half of all CLL patients express this protein, and this population tends to have a more aggressive and harder-to-treat form of the cancer.

Says Dr. Kipps:

By targeting CD44, it may be possible to kill CLL cells regardless of whether there are sufficient numbers of so-called 'effector cells,' which ordinarily are required by other monoclonal antibodies to kill tumor cells. We plan to initiate clinical trials using this humanized anti-CD44 monoclonal antibody in the not-too-distant future.

Source: PNAS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Sitemap